Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT07598734
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Postoperative Knee Function
  • Quality of Life After Primary TKA
  • Sleep Quality Post-TKA

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Doxepin 6 mg — DRUG
    Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
  • Ramelteon 8 mg — DRUG
    Ramelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
  • Placebo Tablets — DRUG
    Placebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty

Study Details

Many patients experience poor sleep during recovery after total knee arthroplasty (TKA). Disturbed sleep can last weeks to months and may worsen pain, slow healing, and reduce overall quality of life. Few safe, effective, evidence-based options exist to improve sleep during this recovery period. This study aims to determine whether the medications doxepin, either alone or in combination with ramelteon, can improve sleep quality during early recovery after TKA. The investigators will also evaluate whether improved sleep leads to better pain control, knee function, and overall quality of life.

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
129 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Doxepin 6 mg
    Participants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
  • Experimental: Doxepin 6 mg and Ramelteon 8mg
    Participants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
  • Placebo Comparator: Placebo
    Participants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.

Primary Outcome Measure

Insomnia Severity Index (ISI) scores (sleep quality) [ Time Frame: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Washington Medical Center Hip & Knee CenterSeattleWashington98133
Portia Morgan
206-668-3674
Nicholas M Hernandez, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Seattle, WA